Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sickle Cell Disease: early-phase trial registry
95 of 214 indexed Sickle Cell Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #43 of 28,707 conditions by registered trial count.
214 US clinical trials · 95 currently recruiting · #43 of 28,707 conditions by registered trial count
Sickle Cell Disease: 214 US clinical trials tracked, 95 recruiting.
Sickle Cell Disease is the subject of 214 registered US clinical trials on ClinicalTrials.gov, 95 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 17 of these trials.
Enrollment posture brief
Registry condition sickle-cell-disease
OPEN 95 | RECR 44% | LATE 14 | EARLY 87 | RANK #43 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Sickle Cell Disease lists 95 open slots (44% of 214 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sickle Cell Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sickle Cell Disease is recruiting above its size-band peers.
95 of 214 indexed trials (44.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Sickle Cell Disease trials is spread across many organizations.
St. Jude Children's Research Hospital accounts for 17 of 214 trials (7.9%). 101 distinct sponsors appear on at least one study for this condition label.
-
Most Sickle Cell Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 214 trials that report a genuine target (sentinel values excluded). 150 of those (70.1%) plan for fewer than 100 participants.
-
Sickle Cell Disease research is mostly interventional.
160 interventional and 54 observational studies make up this index (74.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
214 total, page 4 of 5
Living With Sickle Cell Disease in the COVID-19 Pandemic
National Human Genome Research Institute (NHGRI)
NCT04417673
Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia
Children's Hospital Los Angeles
NCT03715972
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients
Westat
NCT05255445
Decision Aid for Therapeutic Options In Sickle Cell Disease
Emory University
NCT02326597
Validation of the Sickle Cell Disease Pain Burden Interview
Connecticut Children's Medical Center
NCT00804362
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
Pfizer
NCT05036512
The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease
National Heart, Lung, and Blood Institute (NHLBI)
NCT00451919
Sickle Cell Anemia WE CARE
Boston Medical Center
NCT03716726
Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients With Sickle Cell Disease, and Providers Towards the Integration of CRISPR in Clinical Care
National Human Genome Research Institute (NHGRI)
NCT03167450
Arginine Therapy for Sickle Cell Disease Pain
Emory University
NCT02536170
Pathophysiology of Acute Pain in Patients With Sickle Cell Disease
National Heart, Lung, and Blood Institute (NHLBI)
NCT03049475
Molecular Phenotyping of Asthma in Sickle Cell Disease
Nemours Children's Clinic
NCT01879592
A Study to Learn About Sickle Cell Disease In Adult Patients
Pfizer
NCT05407805
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
Medical College of Wisconsin
NCT03263559
Microvascular Blood Flow in Sickle Cell Anemia
Versiti Blood Health
NCT01566890
A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
Icagen
NCT00040677
Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting
St. Jude Children's Research Hospital
NCT01673243
A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease
AstraZeneca
NCT02482298
Sickle Cell Uric Acid (SCUA) - Cohort Repository
Virginia Commonwealth University
NCT04190888
Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease
Children's Hospital Medical Center, Cincinnati
NCT02200510
The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease
St. Jude Children's Research Hospital
NCT01591187
Computerized Cognitive Behavioral Therapy Assisted Life Management for Pain in Sickle Cell Disease
University of Pittsburgh
NCT03029468
Vitamin D for Sickle-cell Respiratory Complications
Gary M Brittenham, MD
NCT01443728
Functional Neuroimaging of Pain Using EEG and fMRI
University of Minnesota
NCT02212691
Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
Jeffrey Glassberg
NCT02061202
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Forma Therapeutics
NCT04987489
BEATS 2: Music Therapy in Sickle Cell
University Hospitals Cleveland Medical Center
NCT03233269
Genes Influencing Iron Overload State
St. Jude Children's Research Hospital
NCT01158794
The Feasibility of the PAINReportIt Guided Relaxation Intervention-INPATIENT
University of Florida
NCT02729350
SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge
Duke University
NCT02475993
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease
National Institutes of Health Clinical Center (CC)
NCT00072826
Evaluation of Sickle Cell Liver Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT01950429
Simvastatin (Zocor) Therapy in Sickle Cell Disease
UCSF Benioff Children's Hospital Oakland
NCT00508027
Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study
Ann & Robert H Lurie Children's Hospital of Chicago
NCT04678037
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Dana-Farber Cancer Institute
NCT01085201
Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial
Vanderbilt University
NCT02187445
Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Duke University
NCT01419977
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
Duke University
NCT05998824
Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)
Laura M. De Castro, MD
NCT01077921
Cognitive Behavioral Therapy and Real-time Self-management Intervention for SCD Via Mobile Applications
University of Pittsburgh
NCT02384590
Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease
CSL Behring
NCT04285827
Motivations, Expectations, and Decision-making of Sickle Cell Patients in Clinical Research
National Institutes of Health Clinical Center (CC)
NCT03709303
Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
Vifor (International)
NCT04817670
Assessing Function in Pediatric Patients With Sickle Cell Disease
Connecticut Children's Medical Center
NCT00590148
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
University of California, San Francisco
NCT03609827
MUSic Therapy to Improve Quality Of Life in Sickle Cell Disease (MUSIQOLS)
University Hospitals Cleveland Medical Center
NCT03556657
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
Monica Bhatia
NCT02867800
Red Blood Cell Survival in Sickle Cell Disease
Marianne Yee
NCT04426591
Stem Cell Transplant for Hemoglobinopathy
Masonic Cancer Center, University of Minnesota
NCT00176852
Use of a Mobile-based App for SCD Patients
Duke University
NCT01833702
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 48 |
| Phase 3 | 11 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Sickle Cell Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sickle Cell Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sickle Cell Disease page
214 registered trials, 95 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 95 Sickle Cell Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Sickle Cell Disease trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sickle Cell Disease condition card totals 214 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.